Table 4. Several imaging agents used in PET/SPECT in some CNS disorders.
| Reference | Imaging agent | PET/SPECT | CNS disorder |
|---|---|---|---|
| Shoghi-Jadid et al., 2002 (14) | 18F-FDDNP | PET | AD |
| Brooks et al., 1990 (15) | 18F-FDOPA | PET | PD |
| Mintun et al., 2006 (16); Klunk et al., 2004 (17) | 11C-PIB | PET | AD |
| Farde et al., 1990 (18); Hirvonen et al., 2008(19) | 11C-raclopride | PET | PD, schizophrenia, depression |
| Banati et al., 2000 (20); Groom et al., 1995 (21) | 11C-PK11195 | PET | AD, MS, Huntington’s disease |
| Savic et al., 1995 (22) | 11C-flumazenil | PET | Epilepsy |
| Kadir et al., 2006 (23) | 11C-nicotine | PET | AD |
| Versijpt et al., 2003 (24) | 123I-iodo-PK11195 | SPECT | AD |
| Arlicot et al., 2008 (25) | 123I-CLINDE | SPECT | AD, MS, Huntington’s disease |
| Booij et al., 1998 (26) | 123I-FP-CIT | SPECT | PD |
| Winogrodzka et al., 2003 (27) | 123I-β-CIT | SPECT | PD |
| Kung et al., 1996 (28) | 99mTc-TRODAT | SPECT | PD |
| Friedland et al., 1997 (29) | 99mTc-10H3 | SPECT | AD |
PET, positron emission tomography; SPECT, single photon emission computed tomography; CNS, central nervous system; AD, Alzheimer’s disease; PD, Parkinson’s disease; MS, multiple sclerosis.